HRSA-J&J Dispute Over 340B Rebate Plan Again Underscores Need For Program Reform

 
• By Cathy Kelly

Johnson & Johnson plans to shift 340B price concessions on Stelara and Xarelto to rebates for some hospitals beginning in October, allowing for more company oversight of claims.

J&J is providing 340B Rebates Instead Of Discounts For Stelara and Xarelto. • Source: Shutterstock

More from Pricing Debate

More from Market Access